(Q37942818)

25 August 2017

1 reference

title

Graft-vs-host disease following allogeneic hematopoietic cell transplantation (English)

1 reference

25 August 2017

Joseph Pidala

1 reference

25 August 2017

publication date

1 October 2011

1 reference

25 August 2017

1 reference

25 August 2017

1 reference

25 August 2017

1 reference

25 August 2017

page(s)

268-276

1 reference

Impending challenges in the hematopoietic stem cell transplantation physician workforce

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Non-HLA immunogenetics in hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Immunogenomics of unrelated hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Pathophysiology of acute graft-versus-host disease: recent advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

New perspectives on the biology of acute GVHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

A biomarker panel for acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Graft-versus-host disease treatment: predictors of survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Antithymocyteglobulin as prophylaxis of graft failure and graft-versus-host disease in recipients of partially T-cell—depleted grafts from matched unrelated donors: A dose-finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Prophylactic antithymocyte globulin reduces the risk of chronic graft-versus-host disease in alternative-donor bone marrow transplants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Strategies to Prevent EBV Reactivation and Posttransplant Lymphoproliferative Disorders (PTLD) after Allogeneic Stem Cell Transplantation in High-Risk Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Sirolimus as primary treatment of acute graft-versus-host disease following allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Glucocorticoid-refractory acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Biology of chronic graft-versus-host disease: implications for a future therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Rituximab for steroid-refractory chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

High levels of B-cell activating factor in patients with active chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Association of Foxp3 regulatory gene expression with graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Duration of immunosuppressive treatment for chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Quality of life after allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Wo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Chronic graft-versus-host disease after allogeneic blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Chronic graft-versus-host disease: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

New classification of chronic GVHD: added clarity from the consensus diagnoses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Diagnosis and clinical management of chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Prophylaxis, empirical therapy, or pre-emptive therapy of fungal infections in immunocompromised patients: which is better for whom?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

Relation of an Interleukin-10 Promoter Polymorphism to Graft-versus-Host Disease and Survival after Hematopoietic-Cell Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800407

10.1177/107327481101800407

21 January 2018

Identifiers

DOI

0 references

1 reference